AlzChem Group AG (0ACT) AI Stock Analysis

2 Followers

AlzChem Group AG

(LSE:0ACT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Specialty chemicals growthSpecialty Chemicals is becoming a larger and more profitable earnings engine, supported by volume growth, favorable mix, high utilization and differentiated products. Its 30% segment EBITDA margin provides a stronger foundation for durable group profitability than lower-margin basic chemicals.

Negative Factors

Weak free cash flowFree cash flow is materially weaker than reported operating cash flow and has deteriorated sharply year over year. This indicates that investment and working-capital needs absorb a substantial portion of earnings, potentially limiting internally funded growth and making shareholder cash returns more cyclical.

AlzChem Group AG (0ACT) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 1.44B
Dividend Yield: 1.47%
Average Volume (3M): 3,813
Price to Earnings (P/E): 23.9
Beta (1Y): 0.42
Revenue Growth: ―
EPS Growth: ―
Country: UK
Employees: 1,765
Sector: Basic Materials
Sector Strength: 61
Industry: Chemicals

AlzChem Group AG Business Overview & Revenue Model

Company Description

Alzchem Group AG engages in the provision of development, production, and marketing of chemical products. It operates through the following segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment fo...

AlzChem Group AG Earnings Call Summary

Earnings Call Date:Jul 30, 2026(Q2-2026)|% Change Since:-17.40%|Next Earnings Date:Nov 12, 2018

Earnings Call SentimentPositive

The call conveyed a broadly positive operational and financial picture: revenue and EBITDA growth, margin expansion, strong Specialty Chemicals momentum, secured financing and clear progress on strategic capacity expansions (Germany and U.S.). Counterbalancing risks include a weak Basics & Intermediates/fertilizer market, one-off refurbishment costs (~EUR 10 million) and timing-related cash/prepayment effects that may soften Q3 and weigh on H2 EBITDA sequencing. Management reaffirmed FY 2026 guidance (sales ~EUR 600m, EBITDA ~EUR 126m), reflecting confidence in underlying drivers while acknowledging near-term headwinds and ramp-up costs.

Positive Updates

Group revenue and earnings growth

Group revenue increased 6% year-on-year to EUR 304.0 million in H1 2026. EBITDA rose 14% to EUR 64.5 million and EBITDA margin expanded from 19.6% to 21.2%. Net income increased ~14% to EUR 35 million (EPS up similarly).

Negative Updates

Basics & Intermediates weakness and near-term profitability drag

Basics & Intermediates revenue declined 4% in H1 to EUR 75.4 million and segment EBITDA was roughly breakeven (vs EUR 1.3 million prior year). Profitability was temporarily burdened by the scheduled carbide furnace refurbishment (maintenance, shutdown costs) and lower regulatory energy benefits during the outage.

Company Guidance

The company confirmed full‑year 2026 guidance of roughly EUR 600 million in sales and about EUR 126 million in EBITDA (implying ~7% sales growth and ~8% EBITDA growth vs. prior year), noting that H1 delivered EUR 304 million sales and EUR 64.5 million EBITDA (H1 EBITDA margin 21.2% vs. 19.6% prior year) with Specialty Chemicals driving performance (H1 specialty sales EUR 214 million, EBITDA ~EUR 64 million, margin ~30%). Management warned Q3 may be softer after some H1 revenue was pulled forward but expects the new nitroguanidine capacity to start contributing in Q4; one‑off furnace refurbishment costs are ~EUR 10 million this year, operating cash flow was EUR 51 million in H1, net income EUR 35 million, equity ratio 40.3%, and a EUR 100 million growth financing package (EUR 80 million disbursed, EUR 20 million committed) was secured.

AlzChem Group AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

GB:0ACT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:FPE	69Neutral	EUR 5.28B	15.81	17.37%	3.26%	12.08%	21.84%
DE:EVK	64Neutral	EUR 9.68B	55.36	2.16%	4.77%	1.98%	83.13%
DE:BNR	62Neutral	EUR 8.89B	23.58	8.30%	3.20%	0.32%	-8.91%
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
DE:WCH	54Neutral	EUR 3.99B	-15.25	-6.82%	3.11%	―	―
DE:LXS	43Neutral	EUR 1.13B	-1.68	-18.99%	0.77%	-3.63%	-172.43%

* Basic Materials Sector Average

Performance Comparison

GB:0ACT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0ACT	AlzChem Group AG	143.74	10.84	8.16%
DE:BNR	Brenntag AG (UK)	59.42	11.21	23.25%
DE:EVK	Evonik Industries AG	20.96	7.70	58.07%
DE:FPE	Fuchs Petrolub	37.45	7.57	25.34%
DE:LXS	Lanxess (OTC)	12.92	-4.95	-27.68%
DE:WCH	Wacker Chemie Ag (OTC)	82.65	16.55	25.04%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AlzChem Group AG AI Stock Analysis